Human pancreatic cancer is a lethal malignancy, and the lesions show a very high incidence of point mutations of the K-ras oncogene. These alterations can be used as potential targets for specific ribozyme (Rz)-mediated growth suppression of the cancer cells. We designed an anti-K-ras Rz against mutant K-ras gene transcripts (codon 12, GGT to GTT) and generated a recombinant adenovirus (rAd) to express the Rz (rAd/anti-K-ras Rz). More than 95% of Capan-1 human pancreatic cells were infected with rAd/anti-K-ras Rz when treated with the virus at 200 plaque-forming units/cell. The virus, rAd/anti-K-ras Rz, significantly suppressed mutant K-ras gene expression and inhibited the growth of Capan-1 cells. At 3 days postinfection, we observed maximum growth suppression of the cells, characteristic morphological changes of apoptosis such as nuclear condensation and oligonucleosomal DNA fragmentation, and suppression of bcl-2 oncoprotein. These changes were not found in control virus-infected cells. Our results indicated that the virus rAd/anti-K-ras Rz specifically down-regulated the K-ras/bcl-2 pathway and induced apoptotic changes in Capan-1 pancreatic carcinoma cells. High-efficiency adenovirus-mediated delivery of anti-K-ras Rz could become a significant gene therapy strategy against human pancreatic cancer. Cancer Gene Therapy (2000) 7, 373-383
H uman pancreatic cancer can be accurately diagnosed using imaging tests such as abdominal ultrasonography, endoscopic retrograde cholangiopancreatography, and computed tomography. 1 However, pancreatic cancer is one of most lethal forms of human cancer, and has a prognosis of Ͻ5% 5-year survival rate because of rapid spread of the tumor, frequent incidence of metastasis, difficulty of early diagnosis, and the limitations of conventional therapy. 2 Pancreatic cancer ranks fifth as a cause of cancer-related mortality in the United States as well as Japan. Development of a new therapeutic strategy for pancreatic cancer (i.e., cancer gene therapy) is one of the most pressing issues in current medicine.
Point mutations in the ras oncogene family activate its p21 gene products and affect the cancer cell growth and malignant phenotype. 3 Characteristically, Ͼ90% of human pancreatic adenocarcinomas contain K-ras gene mutations. 4 -8 For most cases, activated K-ras genes are found with mutations at codon 12. K-ras mutation could occur in the early phase of pancreatic ductal carcinogenesis, because this mutation has also been found in some precancerous pancreatic lesions, such as mucous cell hyperplasia. 9 -11 The activated ras oncoproteins are thought to alter the cellular signal transduction pathways and to affect the neoplastic growth of the pancreatic cancers. Therefore, the mutant K-ras gene transcripts can be used as potential targets of specific gene modulation for suppressing the growth of the pancreatic cancer cells.
Methods for specific gene modulation using oligonucleotides have been developed and have been shown to be useful for suppressing activated oncogenes. [12] [13] [14] Oligonucleotides, including triplex DNAs, antisense nucleotides, and ribozymes (Rzs) (catalytic RNAs), are capable of modulating specific gene expression. 15 Effective and specific gene modulation has been demonstrated using antisense oligonucleotides. 16, 17 Rz strategies have advantages over the use of antisense oligonucleotides because of their site-specific cleavage activities and catalytic potentials. 18, 19 Hammerhead Rzs are derived from satellite RNA of tobacco ringspot virus and are newly developed trans-acting RNA enzymes for the modulation of specific gene expression. 20 Recent studies have indicated the conserved structure of hammerhead Rzs and have shown that hammerhead Rzs contain two functional modules (i.e., a catalytic core that cleaves the target RNA and flanking regions that, by virtue of complementarity, direct the Rz core to a specific target site). 21, 22 Hammerhead Rzs can cleave any triplet of NUX (N ϭ any nucleotide, X ϭ A, C, or U) if the flanking sequence is changed appropriately. Recently, Rzs were reported to be effective against various oncogenes (e.g., c-fos, ras, bcr-abl), [23] [24] [25] [26] [27] against drug-resistance genes (e.g., MDR1), 28, 29 and against HIV-1.
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Our studies demonstrated previously that anti-oncogene Rzs effectively suppress the expression of targeted genes and cause reversal of the malignant phenotype in cancer cells. [32] [33] [34] [35] [36] However, it has not yet been clarified whether apoptotic changes are associated with this Rz-mediated growth suppression of cancer cells.
In this study, we designed an anti-K-ras Rz directed against mutant K-ras mRNA transcripts in human pancreatic carcinoma cells and generated a high-efficiency recombinant adenovirus (rAd) expressing the Rz. Here, we report that the adenovirus (Ad)-mediated anti-K-ras Rz significantly induced apoptosis and growth suppression of human pancreatic carcinoma cells.
MATERIALS AND METHODS

Cells
The Capan-1 human pancreatic carcinoma cell line, which is composed of well-differentiated adenocarcinoma cells, was obtained from the American Type Culture Collection (no. HTB79; Manassas, Va). The cell line was maintained in RPMI 1640 media (Sigma, St. Louis, Mo) containing 15% fetal bovine sera (FBS) (Sigma) as well as 100 international units/mL penicillin and 100 g/mL streptomycin (Life Technologies, Gaithersburg, Md). The cells were found to be free of mycoplasma contamination when tested with a Mycoplasma rapid detection system (Gen-Probe, San Diego, Calif) every 3 months. Genomic DNA of the Capan-1 cells was isolated according to a protocol published previously. 37 To detect mutations at codon 12 of the c-K-ras oncogene in Capan-1 cells, DNA sequencing was performed using a commercial kit (double-stranded DNA (dsDNA) Cycle Sequencing System, Life Technologies).
In vitro cleavage of mutated K-ras RNA by the Rz DNA templates for the in vitro transcription of RNA substrates and hammerhead Rzs were synthesized by 30 cycles of polymerase chain reaction (PCR) (denaturation at 94°C for 60 seconds, annealing at 60°C for 60 seconds, and extension at 72°C for 60 seconds; Perkin-Elmer Cetus, Norwalk, Conn) using the following oligodeoxynucleotide primers: S-Kras-S (5Ј-TAA TAC GAC TCA CTA TAG GAA TAT AAA CTT GTG GTA GTT GGA-3Ј) and S-Kras-A2 (5Ј-GGC ACT CTT GCC TAC GCC AAC AGC TCC AAC T-3Ј) for K-ras RNA (codon 12 mutation, GGT to GTT); Rz-Kras-S (5Ј-TAA TAC  GAC TCA CTA TAG TAC GCC CTG ATG AGT CCG TGA  G-3Ј) and Rz-Kras-A (5Ј-AGC TGT TTC GTC CTC ACG  GAC TCA T-3Ј) for anti-K-ras Rz.
A disabled hammerhead Rz was also synthesized by PCR with the following primers: dRz-Kras-S, 5Ј-TAA TAC GAC  TCA CTA TAG TAC GCC CTA ATG AGT CCG TGA G-3Ј;  Rz-Kras-A, 5Ј-AGC TGT TTC GTC CTC ACG GAC TCA T-3Ј. The disabled Rz contained a single base exchange (G to A) in the catalytic core compared with the original Rz.
PCR products, fractionated through 3% composite agarose gels (2% NuSieve, 1% Seakem; FMC BioProducts, Rockland, Me) and purified by DE52 ion-exchange chromatography, were used as templates for in vitro transcription with T7 RNA polymerase (Stratagene, La Jolla, Calif). The Rzs, disabled Rzs, and substrate RNAs were labeled with [␣-32 P]uridine triphosphate (111 TBq/mmol, Amersham, Little Chalfont, UK) by in vitro transcription. The transcripts (RNA substrates and Rzs) were fractionated through 12% polyacrylamide gels and eluted with 1% sodium dodecyl sulfate (SDS), 0.5 M CH 3 COONH 4 , and 1 mM ethylenediaminetetraacetic acid (EDTA). Cleavage reactions were performed with these RNAs (2 pmol of each); the RNA was combined and heated at 95°C for 2 minutes, quickly cooled on ice, mixed in 10-mL reaction volumes, and incubated under various conditions (Mg 2ϩ concentration: 0 -40 mM; reaction time: 1 minute to 18 hours; RNA substrate to Rz ratio: 1:100; at 37°C) in vitro. The cleavage products were detected by autoradiography (Kodak X-OMAT AR; Eastman Kodak Company, Rochester, NY) after 6% polyacrylamide gel electrophoresis (90 mM tris(hydroxymethyl)aminomethane-borate buffer (pH 8.0), 2 mM EDTA). 38 
Cloning of anti-K-ras Rz
The pACCMVpLpA adenoviral shuttle plasmid vector was kindly provided by Dr. R. Gerard (University of Texas Southwestern Medical Center, Dallas, Tex). 39 Synthesized oligonucleotides were purified according to standard procedures and used for construction of the Rz-expressing adenoviral vector.
The following oligonucleotides were used for the cloning of the anti-K-ras Rz into the pACCMVpLpA plasmid: KrasRz-1, 5Ј-TCG ACT ACG CCC TGA TGA GTC CGT GAG GAC GAA ACA GCT A-3Ј; KrasRz-2, 5Ј-AGC TTA GCT GTT TCG TCC TCA CGG ACT CAT CAG GGC GTA G-3Ј.
Small-or large-scale plasmid DNAs were prepared according to a protocol published previously. 37 To confirm the insert Rz sequences cloned into the pACCMVpLpA plasmid, DNA sequencing was performed using a commercial kit (dsDNA Cycle Sequencing System, Life Technologies).
Generation of rAd
The low-passage 293 E1A-trans-complementing cell line was obtained from Dr. F. Graham (McMaster University, Hamilton, Ontario, Canada) and maintained in Dulbecco's modified Eagle's medium (Sigma) containing 10% FBS (Sigma) as well as 100 international units/mL penicillin and 100 g/mL streptomycin (Life Technologies). To generate the recombinant anti-K-ras Rz-containing Ad, the pACCMVpLpA shuttle plasmid and the pJM17 adenoviral packaging plasmid (kindly provided by Dr. F. Graham, McMaster University) were cotransfected into 293 cells using a commercial cationic liposome vector (Lipofectin Reagent, Life Technologies). 40 Transfected cells were maintained until the onset of cellular cytopathic effects. The newly generated rAd was plaque-purified three times by the standard method. The viral titers were determined by plaque assays as described by Graham and Prevec. 40 
Screening of the Rz expression cassette by PCR
Genomic DNA of the rAd was isolated according to a protocol published previously. 37 The following primers were used to detect the K-ras Rz expression cassette: pACCMV-PCR-1, 5Ј-GCG TGT ACG GTG GGA GGT CT-3Ј; pACCMV-PCR-2, 5Ј-GTT TCG TCC TCA CGG ACT CAT-3Ј. The Rz probe used was: 5Ј-CTC ACG GAC TCA TCA GG-3Ј. Specific PCR products, including the Rz sequence, were detected by Southern blotting with 32 P-labeled oligonucleotide probes, according to a simplified hybridization procedure. 41 The following primers were used to detect the wild-type adenoviral E1A region: E1A-PCR-1, 5Ј-ATT ACC GAA GAA ATG GCC GC-3Ј; E1A-PCR-2, 5Ј-CCC ATT TAA CAC GCC ATG CA-3Ј. This E1A region was predicted to be deleted in the construction of the E1A Ϫ rAd. After validation by PCR analysis, the rAd encoding the anti-K-ras Rz (rAd/anti-K-ras Rz) was expanded on 293 cells and purified by CsCl gradient centrifugation using standard methods. 39 -42 Gene expression of cells treated with rAd
Relative gene expression was evaluated by semiquantitative reverse transcriptase (RT)-PCR assay and radioactive densitometric analysis (Ambis, San Diego, Calif). Poly(A) mRNA of the Capan-1 cells was isolated using a FastTrack mRNA Isolation Kit (Invitrogen, San Diego, Calif), and aliquots of 10 ng of poly(A) mRNA were used as templates for semiquantitative RT-PCR.
Synthesized oligonucleotides were purified by standard procedures and used for the detection of gene expression by RT-PCR, as follows. The following primers were used to detect c-K-ras oncogene expression: Kras-1, 5Ј-GAC TGA ATA TAA ACT TGT GG-3Ј; Kras-2, 5Ј-CTA TTG TTG GAT CAT ATT CG-3Ј. The probe used was Kras-S, 5Ј-TCT GAA TTA GCT GTA TCG TC-3Ј.
The following primers were used to detect phosphoglycerate kinase (PGK) gene expression: PGK-3, 5Ј-AGT CGG TAG TCC TTA TGA GC-3Ј; PGK-4, 5Ј-CAG CAG GAT GAC AGA CCC AG-3Ј. The probe used was PGK-S, 5Ј-GAA CTC AAA TCT CTG CTG GG-3Ј. Specific PCR products were detected by Southern blotting with 32 P-labeled oligonucleotide probes. 41 
Ad-mediated gene transfer in tissue culture
Capan-1 cells were inoculated at a density of 1 ϫ 10 4 cells/dish and treated with rAd/anti-K-ras Rz or rAd vector at 200 plaque-forming units (PFU)/cell. For generation time assay, experiments were performed twice in duplicate.
Phenotype analyses of cells infected with rAd
For thymidine incorporation assay, cells were exposed to 3 H-labeled thymidine (Moravek Biochemicals, Brea, Calif), which was added to the culture media. The cells were treated with ice-cold 10% trichloroacetic acid and 0.2 N NaOH and transferred onto Whatman glass filters (glass microfiber filter, Whatman, Maidstone, UK). The DNA-incorporated 3 H-labeled thymidine was calculated by scintillation counter.
A soft agar colony formation assay was performed according to Kuroki. 43 Capan-1 cells were treated with rAd/anti-K-ras Rz at 200 PFU/cell and plated in triplicate at 5 ϫ 10 3 cells/35-mm dish onto 0.3% agarose supplemented with 10% or 20% FBS. Colonies of the cells were counted at 2 weeks after seeding.
In situ hybridization and immunohistochemistry
Gene expression of rAds was identified by in situ hybridization using the PathoGene DNA Probe Assay and horseradish peroxidase (HRP)-3-amino-9-ethylcarbazole in situ detection system (Enzo, Farmingdale, NY). Capan-1 cells on chamber slides were fixed with 4% paraformaldehyde (PFA) for 30 minutes. Ad DNA probe solution was dropped onto the slides. Next, the specimens were heated for 5 minutes at 95°C and for 60 minutes at 37°C, then reacted with streptavidin-biotinylated HRP complex for 60 minutes at 37°C. Ad gene expression was visualized using aminoethylcarbazole and detected as a localized brick red precipitate on the specimens. rAd in the infected Capan-1 cells was detected by an indirect immunohistochemical method. Anti-Ad monoclonal antibody (mAb) (1/800 dilution; Chemicon, Temecula, Calif) was used as the primary antibody (Ab). Ad gene transfer was visualized using 3,3Ј-diaminobenzidine tetrahydrochloride (DAB).
A catalytic signal amplification system (Dako, Carpinteria, Calif) detected bcl-2 oncoprotein in the Capan-1 cells. Antihuman bcl-2 mAb (1/10 dilution; Dako) was used as the primary Ab and visualized by DAB.
Western blot analysis
Total cell lysate was prepared with lysate buffer (10 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.4), 1% Nonidet P-40, 0.1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 1 mM EDTA, 2 g/mL aprotinin, 2 g/mL leupeptin, 0.5 g/mL chymostatin, and 1 mM phenylmethylsulfonyl fluoride). A total of 10 g of protein was separated on 12.5% SDS-polyacrylamide gels and transferred to Hybond-P (Amersham) using the Mini-Protean II system (Bio-Rad, Hercules, Calif). After blocking with 3% bovine serum albumin/phosphate-buffered saline (PBS) and 2% normal goat sera, the blot was incubated with anti-human bcl-2 mAb (1:300; Dako). Next, HRP-conjugated anti-mouse immunoglobulin (1:5000; Amersham) was applied. bcl 2 signals were detected using an enhanced chemiluminescence plus system (Amersham) and Kodak AR film (Eastman Kodak Company).
Cytochemistry to observe morphological signs of apoptosis
A multistage process of apoptotic DNA fragmentation was confirmed by the terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate-biotin nick end-labeling (TUNEL) method using an ApopTaq Plus In Situ Apoptosis Detection Kit (Oncor, Gaithersburg, Md). The Capan-1 cells on chamber slides were fixed with 4% PFA for 30 minutes, washed in PBS (pH 7.4), and quenched in 0.3% hydrogen peroxide in methanol for 5 minutes at room temperature. The specimens were then immersed in TdT buffer for 10 minutes at room temperature, reacted with a mixture of digoxigeninlabeled nucleotides and TdT enzyme for 60 minutes at 37°C, and treated with anti-digoxigenin Ab peroxidase conjugate for 30 minutes at room temperature. Apoptosis was detected by color development using DAB.
Transmission electron microscopy
The Capan-1 cells were washed with PBS, prefixed in modified Karnovsky solution (2% PFA, 0.5% glutaraldehyde, 40 mM phosphate buffer (pH 7.4), and 150 mM NaCl) for 24 hours, and postfixed with 1% OsO4 for 1 hour at room temperature. The fixed cells were dehydrated in ethanol and embedded in Quetol-812 (Nisshin EM, Tokyo, Japan). Ultrathin sections were stained with uranyl acetate and lead citrate and subsequently examined with a transmission electron microscope (Model JEM-1200EX, JEOL, Tokyo, Japan).
RESULTS
Design of a hammerhead Rz against activated K-ras mRNA
We designed an anti-K-ras hammerhead Rz targeted against activated human K-ras mRNA (codon 12, GGU to GUU; cleavage between nucleotide positions ϩ6412 and ϩ6413) (Fig 1) . We also designed disabled mutants of the anti-K-ras Rz (disabled Rz) in which the functionally indispensable residue G in the consensus loop was replaced by another nucleotide, A.
dsDNA cycle sequencing demonstrated that genomic DNA of the Capan-1 cells had a GTT homozygous mutation of the K-ras oncogene at codon 12, which encodes a valine residue (data not shown). The mRNA transcript of GTT mutation was a cleavable sequence by the anti-K-ras Rz designed as described above.
Cleavage by anti-K-ras Rz in a cell-free system To examine the actual enzymatic activity of the designed Rzs, we carried out in vitro cleavage by the Rz in a cell-free system (Fig 2) . The anti-K-ras Rz specifically cleaved synthetic activated K-ras RNA (codon 12, GGU to GUU). In vitro cleavage efficiency was dependent upon the Mg 2ϩ concentration and the Rz/mutant K-ras RNA ratio (data not shown). In contrast, the disabled Rz did not cleave synthetic activated K-ras RNA in vitro.
Generation of rAd expressing the anti-K-ras Rz (rAd/anti-K-ras Rz) Double-stranded oligonucleotides, including anti-K-ras Rz sequences, were cloned into the pACCMVpLpA Ad shuttle plasmid (Fig 1) . The methodology for rAd construction was based on in vivo homologous recombination between the adenoviral shuttle vector pACCMVpLpA and the adenoviral packaging plasmid pJM17. The newly generated rAd (rAd/anti-K-ras Rz) was predicted to contain the anti-K-ras Rz expression cassette inserted in place of the deleted adenoviral E1 region, and to be replication-defective. The PCR assay of viral DNA demonstrated the presence of the anti-K-ras Rz in the rAd (data not shown). A rAd expressing the disabled Rz, rAd/disabled Rz, and a rAd without E1 and Rz sequences, rAd/vector, were prepared as controls.
Gene transfer efficiency of rAd/anti-K-ras Rz and suppression of target mRNA
The Capan-1 cells at 80% confluency were infected with rAd/anti-K-ras Rz, rAd/vector, or rAd/disabled Rz at multiplicity of infection (MOI) of 200 PFU/cells. At 2 days postinfection, the treated cells were subjected to in situ hybridization or immunohistochemical analysis. More than 95% of the treated Capan-1 cells had positive signals for Ad mRNA or its gene products, and were infected with rAd/anti-K-ras Rz, rAd/vector, or rAd/ disabled Rz (Fig 3) .
Relevant gene expression in the Capan-1 cells was analyzed by semiquantitative RT-PCR (Fig 4) . The Capan-1 cells treated with rAd/anti-K-ras Rz exhibited abundant expression of the anti-K-ras Rz and decreased K-ras gene expression. The down-regulation of K-ras 
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gene expression was maximal at 2 days postinfection, and exhibited a sharp reversal after day 5 (Fig 5) . In contrast, rAd/vector or rAd/disabled Rz did not downregulate K-ras gene expression, although most Capan-1 cells were infected with rAd.
Growth suppression of Capan-1 cells induced by rAd/anti-K-ras Rz infection
Growth curves of the Capan-1 cells are shown in Figure  6 . The Capan-1 cells showed significant growth suppression after treatment with rAd/anti-K-ras Rz at an MOI of 200 PFU/cells. Maximum growth suppression was observed at 3 days postinfection. The Capan-1 cells treated with rAd/anti-K-ras Rz slowly regrew after day 5. In contrast, the Capan-1 cells treated with rAd/vector grew well similarly to controls without Ad treatment (mock infection).
The generation time of the Capan-1 cells treated with rAd/anti-K-ras Rz (255 hours) was significantly longer (4.3-fold) than that of controls (59 hours; between day 7 and day 9) ( Table 1) . At 2 days postinfection, the Capan-1 cells treated with rAd/anti-K-ras Rz showed a 47% decrease in thymidine incorporation. Colonies of Capan-1 cells infected with rAd/anti-K-ras in soft agar were substantially decreased in number compared with the controls (82% decrease).
Apoptosis of Capan-1 cells induced by rAd/anti-K-ras Rz infection
The Capan-1 cells treated with rAd/anti-K-ras Rz, rAd/ vector, or rAd/disabled Rz were subjected to cytochemical and electron microscopic analyses to detect apoptosis. Several apoptotic cells treated with rAd/anti-K-ras Rz were observed at 2 days postinfection. Apoptosis was more frequently found at 3 days postinfection, and the percent of apoptotic cells was 17.5% (Fig 7) . Double cytochemical staining demonstrated apoptosis and rAd/ anti-K-ras Rz infection in the same cells. The Capan-1 cells treated with rAd/anti-K-ras Rz showed a significant decrease in bcl-2 oncoprotein expression (Fig 8) . The p53 and c-myc expression was not changed in the Capan-1 cells infected with rAd/anti-K-ras Rz compared with rAd/vector treatment (data not shown). Oligonucleosomal DNA fragmentation was observed at 3 days postinfection in cells treated with rAd/anti-K-ras Rz (Figs 9 and 10 ). In contrast, few apoptotic cells and no oligonucleosomal DNA ladder formation were noted in cultures treated with rAd/vector or rAd/disabled Rz.
DISCUSSION
We constructed a hammerhead Rz to cleave the activated K-ras mRNA transcripts and examined the efficiency of cleavage by this Rz in a cell-free system and its biological effects in the Capan-1 human pancreatic carcinoma cell line using an adenoviral gene delivery system. We demonstrated that the Rz down-regulated activated K-ras mRNA and significantly induced apopto- sis and growth suppression of the Capan-1 human pancreatic carcinoma cells. This is the first study to confirm modulation of apoptosis of pancreatic cancer cells by an anti-K-ras Rz, and this effect was correlated with decreases in the levels of K-ras and bcl-2 gene expression. Specific gene modulation using antisense oligonucleotides has been demonstrated to be a useful strategy for suppressing activated oncogenes. 16,17,44 -46 Rz strategies have advantages over the use of antisense oligonucleotides because of their site-specific cleavage activities and catalytic potentials. 15, 18, 19 Previous studies indicated that anti-oncogene Rzs effectively suppress the expression of targeted genes and cause reversal of the malignant phenotype in cancer cells. [23] [24] [25] [32] [33] [34] [35] [36] 47 However, it has not yet been clarified whether apoptosis is associated with this Rz-mediated growth suppression of the cancer cells.
Point mutations of the K-ras at codon 12 are found in most human pancreatic carcinomas, and activate its p21 oncogene products. [3] [4] [5] [6] [7] [8] This mutant mRNA is a likely target for Rz-mediated gene modulation, because the activated ras oncoproteins are thought to alter the cellular signal transduction pathways and to affect the neoplastic growth of pancreatic cancers. The anti-Kras hammerhead Rz we designed efficiently cleaved the target mutant K-ras RNA in the cell-free system. For the cell culture study, we used a rAd as a delivery system for the Rz because the ultimate goal of this study was therapeutic application of the anti-K-ras Rz in human pancreatic cancer.
We cloned the anti-K-ras Rz sequence into the adenoviral vector and generated rAd/anti-K-ras Rz. The adenoviral vector is driven by the cytomegalovirus (CMV) early promoter/enhancer, contains the polyadenylation signal from simian virus 40, and usually expresses its insert at high levels in human cells. 35,48 -50 The expression cassette replaced the adenoviral E1 region, rendering rAd/anti-K-ras Rz replication-deficient. We demonstrated high-level expression of anti-K-ras Rz and down-regulated K-ras mRNA in Capan-1 human pancreatic carcinoma cells treated with rAd/anti-K-ras Rz at the optimal MOI of 200 PFU/cells. The Capan-1 cells were infected with rAd/anti-K-ras Rz at different MOIs in a preliminary study (data not shown). The MOI of 200 PFU/cells that we used was on a dose plateau to achieve Ͼ95% transduction, and exhibited a strong cytocidal effect without apparent cytotoxicity. The MOI of 200 PFU/cells was thought be optimal and was within the range (30 -500 PFU/cell) reported in previous studies. 35,48 -50 The duration of the down-regulation of K-ras mRNA after adenoviral infection was Ͼ10 days. However, the K-ras down-regulation was rapidly weakened at 5 days postinfection. rAds are nonintegrative gene transfer vectors. Therefore, the Rz expression and down-regulation of K-ras transcripts were transient. This might be due to degradation of adenoviral DNA or to a dilution effect of the continuous growth of noninfected cells. Previous studies demonstrated data similar to our results with adenoviral gene transfer, although several investigators detected a longer-term expression of transferred genes. 50 -52 The duration of the adenovirus-mediated gene transfer depends upon a number of factors such as the host cells, the genes transferred, and the promoter activity.
In a tissue culture study, we demonstrated high efficacy of rAd/anti-K-ras Rz. The Capan-1 pancreatic carcinoma cells were effectively infected with rAd/anti-K-ras Rz, and their generation time was significantly longer (4.3-fold) than that of control cells. Interestingly, the maximum growth suppression of the cells was found at 3 days postinfection, which was delayed by 1 day after maximum K-ras gene down-regulation in addition to a high frequency of apoptosis. The virus rAd/anti-K-ras Rz affected not only cell growth but also other growth characteristics, such as thymidine incorporation and soft agar colony formation.
Next, we analyzed whether the cytocidal effects resulted from the apoptotic changes induced by rAd/anti-K-ras Rz. Several studies have demonstrated that the activated ras oncoprotein was capable of inducing bcl-2 gene expression and inhibiting apoptosis. [53] [54] [55] We hypothesized that down-regulated ras gene expression might be capable of suppressing bcl-2 gene expression and inducing apoptosis. The Capan-1 cells infected with rAd/anti-K-ras Rz manifested apoptosis after 2 days postinfection. The virus and apoptosis were demonstrated to be in the same cells by double cytochemical staining. We also confirmed the occurrence of apoptosis as characterized by nuclear fragmentation, chromatin condensation, and nucleosomal DNA fragmentation by morphological analyses, TUNEL staining, and DNA ladder formation, as well as down-regulation of bcl-2 expression. These results were compatible with the previous observation that the apoptosis pathway is related to activated ras and bcl-2 gene expression. [53] [54] [55] There are multiple pathways for induction of apoptosis. The p53 and c-myc genes are thought to be upstream of bcl-2. In the present study, we found no changes in p53 or c-myc gene expression. The adenovirus-mediated expression of the anti-K-ras Rz, therefore, induced the observed cytocidal effects in the Capan-1 pancreatic carcinoma cells through a mechanism of apoptosis that appeared to be bcl-2-dependent and p53-independent.
This Rz-mediated specific gene modulation against the mutant K-ras mRNA was capable of reversing the malignant phenotype of human pancreatic carcinoma cells through a mechanism of apoptosis. Thus, this anti-K-ras Rz may be useful for limiting the growth of pancreatic tumors. Using this adenoviral vector, we demonstrated high-efficiency delivery of the anti-K-ras Rz into human pancreatic carcinoma cells. However, the adenovirus vector used was driven by the CMV early promoter/enhancer, and not by a tissue-specific promoter. 56, 57 For future clinical application of Rz-mediated gene modulation, it will be necessary to investigate the activities of tissue-specific promoters. One potentially useful promoter is the carcinoembryonic antigen promoter, because pancreatic carcinomas frequently produce large amounts of carcinoembryonic antigen. 58, 59 When targeted against a tumor-selective gene and placed under the control of a tissue-specific promoter, Rzs offer minimal toxicity for application in cancer gene therapy. 
